MX2020013282A - Forma de dosificacion que comprende un producto bioterapeutico vivo. - Google Patents

Forma de dosificacion que comprende un producto bioterapeutico vivo.

Info

Publication number
MX2020013282A
MX2020013282A MX2020013282A MX2020013282A MX2020013282A MX 2020013282 A MX2020013282 A MX 2020013282A MX 2020013282 A MX2020013282 A MX 2020013282A MX 2020013282 A MX2020013282 A MX 2020013282A MX 2020013282 A MX2020013282 A MX 2020013282A
Authority
MX
Mexico
Prior art keywords
dosage form
live biotherapeutic
biotherapeutic product
product
live
Prior art date
Application number
MX2020013282A
Other languages
English (en)
Inventor
Christophe Carite
Sophie Declomesnil
Original Assignee
4D Pharma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1810061.0A external-priority patent/GB201810061D0/en
Priority claimed from GBGB1818740.1A external-priority patent/GB201818740D0/en
Application filed by 4D Pharma Res Ltd filed Critical 4D Pharma Res Ltd
Publication of MX2020013282A publication Critical patent/MX2020013282A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención proporciona una forma de dosificación entérica que comprende un producto bioterapéutico vivo.
MX2020013282A 2018-06-19 2019-06-19 Forma de dosificacion que comprende un producto bioterapeutico vivo. MX2020013282A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1810061.0A GB201810061D0 (en) 2018-06-19 2018-06-19 Product
GBGB1818740.1A GB201818740D0 (en) 2018-11-16 2018-11-16 Product
PCT/GB2019/051720 WO2019243814A1 (en) 2018-06-19 2019-06-19 Dosage form comprising a live biotherapeutic product

Publications (1)

Publication Number Publication Date
MX2020013282A true MX2020013282A (es) 2021-02-22

Family

ID=67107909

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013282A MX2020013282A (es) 2018-06-19 2019-06-19 Forma de dosificacion que comprende un producto bioterapeutico vivo.

Country Status (13)

Country Link
US (1) US20210196643A1 (es)
EP (1) EP3810097A1 (es)
JP (1) JP2021527639A (es)
KR (1) KR20210021461A (es)
CN (1) CN112312896A (es)
AU (1) AU2019289190A1 (es)
BR (1) BR112020025123A2 (es)
CA (1) CA3103064A1 (es)
IL (1) IL279190A (es)
MX (1) MX2020013282A (es)
SG (1) SG11202012621VA (es)
TW (1) TW202007400A (es)
WO (1) WO2019243814A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117797176A (zh) * 2024-03-01 2024-04-02 南京大学 双胞梭菌在制备治疗非酒精性脂肪性肝病药物中的应用和一种药物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
US20050266069A1 (en) * 2002-09-06 2005-12-01 Simmons Donald L Stable probiotic microsphere compositions and their methods of preparation
GB2418431A (en) * 2004-09-27 2006-03-29 Multigerm Uk Entpr Ltd Metabolically active micro organisms and methods for their production
US9492487B2 (en) * 2010-02-01 2016-11-15 Matthew Ryan Garner Microbial product containing multiple microorganisms
EP2722104B1 (en) 2010-10-26 2018-03-07 Capsugel Belgium NV Bulk Enteric Capsule Shells
CN102210659B (zh) * 2011-06-02 2012-07-04 陕西巨子生物技术有限公司 一种双歧杆菌微胶囊及其制备方法
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN102960598A (zh) * 2012-11-19 2013-03-13 陕西科技大学 一种三层包埋双歧杆菌微胶囊的制备方法
CN102960600A (zh) * 2012-11-19 2013-03-13 陕西科技大学 一种双层包埋双歧杆菌微胶囊的制备方法
EP2951285A4 (en) * 2013-02-04 2016-10-26 Seres Therapeutics Inc COMPOSITIONS AND METHODS FOR INHIBITING THE GROWTH OF PATHOGENIC BACTERIA
MA41010B1 (fr) * 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HUE044617T2 (hu) 2015-06-15 2019-11-28 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
MD3209310T2 (ro) 2015-11-20 2018-06-30 4D Pharma Res Ltd Compoziții care conțin tulpini bacteriene
CN114712405A (zh) * 2016-03-04 2022-07-08 4D制药有限公司 包含细菌菌株的组合物
FI3468573T3 (fi) * 2016-06-14 2023-10-02 Vedanta Biosciences Inc Clostridium difficile -infektion hoito
TWI802545B (zh) * 2016-07-13 2023-05-21 英商4D製藥有限公司 包含細菌菌株之組合物

Also Published As

Publication number Publication date
EP3810097A1 (en) 2021-04-28
KR20210021461A (ko) 2021-02-26
IL279190A (en) 2021-01-31
JP2021527639A (ja) 2021-10-14
AU2019289190A1 (en) 2021-01-07
SG11202012621VA (en) 2021-01-28
US20210196643A1 (en) 2021-07-01
CN112312896A (zh) 2021-02-02
WO2019243814A1 (en) 2019-12-26
BR112020025123A2 (pt) 2021-03-23
CA3103064A1 (en) 2019-12-26
TW202007400A (zh) 2020-02-16

Similar Documents

Publication Publication Date Title
MX2020003760A (es) Formulaciones de niraparib.
MX2020003712A (es) Union giratoria de pasaje multiple.
MX2020004424A (es) Formulacion aerosolizable.
SG11202108635XA (en) Decentralized processing of interactions on delivery
MX2020013282A (es) Forma de dosificacion que comprende un producto bioterapeutico vivo.
GB202015822D0 (en) 66.123.142648/01
EA202190065A1 (ru) Лекарственная форма, содержащая живой биотерапевтический продукт
GB201812049D0 (en) Pesticidal dosage form
CA190068S (en) Tablet cover
GB201819687D0 (en) Mrbr.5
GB201814638D0 (en) Invention 9.9.18
GB201812935D0 (en) Invention 8.8.18
GB2572624B (en) Descriptor generation
GB201906713D0 (en) Collider
GB201814381D0 (en) Packaging 28
GB201814342D0 (en) Packaging 30
GB201814417D0 (en) Packaging 33
GB201814405D0 (en) Packaging 21
GB201814404D0 (en) Packaging 20
GB201814400D0 (en) Packaging 10
GB201814380D0 (en) Packaging 18
GB201807106D0 (en) Packing four
GB201807003D0 (en) LENR the atmospheric assemelater
GB201807110D0 (en) Packaging 25
GB201807091D0 (en) Packaging 22